04th week of 2012 patent applcation highlights part 47 |
Patent application number | Title | Published |
20120021947 | System and Method to Obtain Oligo-Peptides with Specific High Affinity to Query Proteins - This application is based on the concept of the Proteomic Code, PC (discovered and described by Biro, 1981-2011, for review see ref 6) and making use of the biological observation, that co-locating amino acids [in interacting proteins] are coded by partially complementary codons. A method is provided to design and produce a special and distinct set of affinity oligopeptides (AffiSeq) using the PC principle. These designed and artificially produced affinity peptides will be used in any biotechnological or pharmacological applications which benefit of the specific and high affinity protein-protein interactions. | 2012-01-26 |
20120021948 | SURFACE DISPLAY OF WHOLE ANTIBODIES IN EUKARYOTES - Methods for display of recombinant whole immunoglobulins or immunoglobulin libraries on the surface of eukaryote host cells, including yeast and filamentous fungi, are described. The methods are useful for screening libraries of recombinant immunoglobulins in eukaryote host cells to identify immunoglobulins that are specific for an antigen of interest. | 2012-01-26 |
20120021949 | Methylation Ligation-Dependent Macroarray (MLM) - A method is disclosed for detecting the presence of a methylated site at a specific location on a single stranded target nucleic acid sequence. Further disclosed are nucleic acid probes for use in the method and a kit for performing the method. | 2012-01-26 |
20120021950 | Expression Vector - An expression vector including two separately inducible converging promoters P1 and P2, and expression system including such an expression vector and an additional regulator vector, a method of protein expression using such an expression system, and a method of investigating (meta)genome libraries using such an expression system. | 2012-01-26 |
20120021951 | Apparatus for Assay, Synthesis and Storage, and Methods of Manufacture, Use, and Manipulation Thereof - The invention features methods of making devices, or “platens”, having a high-density array of through-holes, as well as methods of cleaning and refurbishing the surfaces of the platens. The invention further features methods of making high-density arrays of chemical, biochemical, and biological compounds, having many advantages over conventional, lower-density arrays. The invention includes methods by which many physical, chemical or biological transformations can be implemented in serial or in parallel within each addressable through-hole of the devices. Additionally, the invention includes methods of analyzing the contents of the array, including assaying of physical properties of the samples. | 2012-01-26 |
20120021952 | FOCUSED LIBRARIES OF GENETIC PACKAGES - Focused libraries of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of antibody peptides, polypeptides or proteins and collectively display, display and express, or comprise at least a portion of the focused diversity of the family. The libraries have length and sequence diversities that mimic that found in native human antibodies. | 2012-01-26 |
20120021953 | Rapid Subcloning Using Site-Specific Recombination - The present invention provides compositions, including vectors, and methods for the rapid subcloning of nucleic acid sequences in vivo and in vitro. In particular, the invention provides vectors used to contain a gene of interest that comprise a sequence-specific recombinase target site. These vectors are used to rapidly transfer the gene or genes of interest into any vector that contains a sequence-specific recombinase target site located downstream of a regulatory element so that the gene of interest may be regulated. | 2012-01-26 |
20120021954 | FORMATION OF ORGANIC NANOSTRUCTURE ARRAY - A nanostructure array is disclosed. The nanostructure array comprises a plurality of elongated organic nanostructures arranged generally perpendicularly to a plane. | 2012-01-26 |
20120021955 | ANTI-SEIZING AGENT, SENSOR AND ASSEMBLY INCLUDING SENSOR - An anti-seizing agent including: a first solid lubricant containing at least one of bismuth and a bismuth compound; and a second solid lubricant containing at least one of graphite, molybdenum disulfide and boron nitride. The anti-seizing agent satisfies the relationships 20 weight %≦a≦90 weight % and 10 weight %≦d≦80 weight %, in which a sum of the contents of the first solid lubricant and the second solid lubricant in the anti-seizing agent is taken as 100 weight %, and a represents a content of the first solid lubricant and d represents a content of the second solid lubricant. | 2012-01-26 |
20120021956 | Composition Containing Ester Compounds and a Method of Lubricating an Internal Combustion Engine - The invention provides a lubricating composition containing a ?-amino compound. The invention further relates to a method of lubricating an internal combustion engine by lubricating the engine with the lubricating composition. The invention further relates to the use of the β-amino carbonyl compound as copper corrosion inhibitors, friction control agents, antiwear and/or extreme pressure agents. | 2012-01-26 |
20120021957 | IONIC LIQUIDS HAVING A CONTENT OF IONIC POLYMERS - Method of adjusting the viscosity of a salt having a melting point of less than 100° C. at atmospheric pressure (referred to as ionic liquid for short), wherein an oligomeric or polymeric compound which has a content of at least 0.01 mol of covalently bound acid groups/100 g of compound with at least 1% of the acid groups being present as a salt with an organic cation comprising at least one heteroatom selected from among nitrogen, oxygen, sulfur and phosphorus is added to the ionic liquid. | 2012-01-26 |
20120021958 | Oxalic Acid Bis-Amides or Amide-Ester as Friction Modifiers in Lubricants - A composition is provided suitable for use as a friction modifier for an automatic transmission, comprising an N-substituted oxalic acid bisamide or amide-ester containing at least two hydrocarbyl groups of 12 to 22 carbon atoms. | 2012-01-26 |
20120021959 | Muttiple Use Fabric Conditioning Composition With Blooming Perfume - Multiple use fabric conditioning composition. | 2012-01-26 |
20120021960 | AQUEOUS HAIR AND SKIN CLEANSING COMPOSITIONS - The present invention relates to an aqueous composition comprising: i) 0.5 to 10 mass percent of at least one sulfo-succinate surfactant; ii) 0.5 to 10 mass percent of at least one amphoteric surfactant; and iii) free, OH-functional compounds similar to the alcohol component of the esters of the sulfosuccinate surfectants that are employed, wherein the mass ratio of sulfosuccinate surfectant i) to the free, OH-functional compound ranges from 100:1 to 100:20. The invention further relates to the use of such a composition for producing cleansing compositions, or as cleansing compositions, in particular for the cleansing of skin and hair, and to skin and/or hair cleansing agents containing such a composition. | 2012-01-26 |
20120021961 | COMPOSITION FOR POST CHEMICAL-MECHANICAL POLISHING CLEANING - The present invention relates to a composition for post chemical-mechanical polishing (CMP) cleaning. The composition is alkaline, which can remove azole-type corrosion inhibitors on the wafer surface after CMP. This composition can effectively remove azole compounds, increase wettability of the Cu surface, and significantly improve the defect removal after CMP. | 2012-01-26 |
20120021962 | GLYCEROL LEVULINATE KETALS AND THEIR USE - The present disclosure relates to the preparation of ketal compounds from glycerol and levulinic acid and esters, and uses thereof. | 2012-01-26 |
20120021963 | Biodegradable concentrated neutral detergent composition - A biodegradable concentrated neutral detergent composition comprises various chelate compounds, various corrosion inhibitors, an alkaline compound, at least one sequestrant, various surfactants and hydrotropes, and water. The detergent can be highly concentrated, has a good long term shelf life, and when diluted is very effective in cleaning metals such as surgical instruments and prevents corrosion resistance of the metal even in a hard water environment. | 2012-01-26 |
20120021964 | TRIGGERED RELEASE - A method is described for delivering a species to a liquid, whereby porous particles are exposed to a condition such that the species is rapidly released into the liquid. Each of the porous particles comprises an agglomeration of primary particles so that outer surfaces of said primary particles define pores of said porous particles. The primary particles comprise silica and the species is disposed in the pores of the porous particles. | 2012-01-26 |
20120021965 | CLEANING AGENT - Liquid detergent or cleaning agent preparations include a) at least 5 wt % of at least one enzyme preparation active in washing or cleaning; and b) at least 0.5 wt % cumenesulfonate, wherein the liquid detergent or cleaning agent preparations are characterized by a good phase stability and enzyme stability and good cleaning performance. | 2012-01-26 |
20120021966 | SILICAS AND ALKALI METAL SALT COMPOSITIONS, DETERGENTS FORMED FROM SUCH COMPOSITIONS AND METHOD OF FORMING SUCH COMPOSITIONS AND DETERGENTS - The current disclosure relates to a silica-based particle containing at least approximately 5% silica by solid weight, at least approximately 15% alkali metal salt by solid weight; and at least approximately 15% water by total weight. Another embodiment of the disclosure relates to a detergent containing a silica/alkali metal salt particle and also containing at least a surfactant. Still another embodiment relates to a method of producing a silica/alkali metal salt particle. According to the method, one may combine a metal silicate and an amount of at least one acid source sufficient to form silica from the silicate and at least one alkali metal salt from the metal and acid, precipitate the silica to form precipitated silica, and, without washing the precipitated silica to remove the alkali metal salt, form a particle comprising the precipitated silica and at least approximately 15% alkali metal salt by solid weight. | 2012-01-26 |
20120021967 | SYNTHETIC ANTIBODIES - The present invention provides methods for synthetic antibodies, methods for making synthetic antibodies, methods for identifying ligands, and related methods and reagents. | 2012-01-26 |
20120021968 | METHODS FOR TREATING OR PREVENTING UROLOGICAL INFLAMMATION - Described herein are methods for treating or preventing urological inflammation in a subject comprising administering to the subject an effective amount of a compound comprising
| 2012-01-26 |
20120021969 | PROSTHETIC IMPLANT SHELL - Methods for improving ejaculate of a patient in need thereof are presented, more particularly, methods for increasing ejaculate volume/prostatic fluid to increase viability of sperm contained therein by administration of a neurotoxin to the prostate of the patient, are provided. | 2012-01-26 |
20120021970 | METHODS FOR PREVENTING OR TREATING MITOCHONDRIAL PERMEABILITY TRANSITION - The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p | 2012-01-26 |
20120021971 | Functional Food Product Comprising Heat Shock Protein or a Hydrolysate Thereof - The invention relates to a heat shock protein from alfalfa and/or a hydrolysate of a heat shock protein from alfalfa in the manufacture of a food product for the prophylactic or therapeutic treatment of a chronic inflammatory disorder. Further, the invention relates to a clinical food product comprising heat shock protein from alfalfa and/or a hydrolysate of a heat shock protein from alfalfa. | 2012-01-26 |
20120021972 | PEPTIDOMIMETICS WITH GLUCAGON ANTAGONISTIC AND GLP 1 AGONISTIC ACTIVITIES - The present invention provides novel peptidomimetics, of formula (I), which primarily act as glucose dependent insulin secretagogues. Furthermore, it was found that these peptidomimetics showed glucagon receptor antagonistic activity, along with the GLP-I receptor agonistic activity. | 2012-01-26 |
20120021973 | Peptides for Treatment of Obesity - The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity. | 2012-01-26 |
20120021974 | NOVEL INHIBITOR OF ANGIOGENESIS - The invention relates to a method of treatment for states related to inhibition of angiogenesis and endothelial cell proliferation comprising administering an effective amount of vimentin or its derivatives or its fragments, to a subject in need thereof. Further, the invention relates to a pharmaceutical composition and a medicament comprising vimentin, as well as the use of vimentin in the manufacture of a medicament. Hereby, angiogenesis and endothelial cell proliferation can be controlled, and therapeutic treatment for related states is provided. | 2012-01-26 |
20120021975 | ANTIBIOTIC PEPTIDES - The invention relates to a peptide or peptide derivative having the general formula: Sub | 2012-01-26 |
20120021976 | BICYCLIC PIPERIDINE AND PIPERAZINE DERIVATIVES AS GPCR MODULATORS FOR THE TREATMENT OF OBESITY, DIABETES AND OTHER METABOLIC DISORDERS - The present invention relates to Bicyclic Piperidine and piperazine Derivatives, compositions comprising a Bicyclic Piperidine and piperazine Derivative, and methods of using the Bicyclic Piperidine and piperazine Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a GPCR in a patient. | 2012-01-26 |
20120021977 | PROMOTION OF HEALTHY CATCH-UP GROWTH - The use of a protein source comprising bovine casein proteins for the preparation of a nutrional composition for administration to an infant, young child or adult during or after a period of catch-up growth or weight recovery, following a period of growth restriction or weight lost, so as improve growth at early age and/or to reduce the risk of development of insulin resistance and/or Type 2 diabetes later in the life of the infant, young child or adult. | 2012-01-26 |
20120021978 | COMBINATION OF AN INSULIN AND A GLP-1-AGONIST - The invention relates to a drug comprising at least one insulin and at least one GLP-1 receptor agonist. | 2012-01-26 |
20120021980 | COMPOSITIONS FOR DRUG ADMINISTRATION - The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms. In various aspects, the invention provides compositions and methods for oral delivery of glucagon-like peptide-1 analogs, such as exenatide, albiglutide, taspoglutide, liraglutide and lixisenatide. | 2012-01-26 |
20120021981 | COMPOSITIONS TO PREVENT AND TREAT TYPE-1 DIABETES - The present invention is based on the discovery that Humanin and humanin analogues protect pancreatic beta cells in vitro and in vivo from apoptosis. Accordingly, humanin and its analogues are useful for preventing and treating diabetes and promoting beta cell survival in a number of applications. | 2012-01-26 |
20120021982 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION - The present invention features pharmaceutical compositions and methods of using the pharmaceutical compositions for treating left ventricular diastolic dysfunction. In particular, the pharmaceutical compositions include an apolipoprotein complex comprising a lipid fraction and a protein fraction. | 2012-01-26 |
20120021983 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND PROGNOSIS OF CANCER AND PROGRESSION, AND FOR SCREENING ANTI-CANCER AGENTS - MicroRNA (miRNA) profiling of cells showed unique miRNA signatures for each of three Akt isoforms. Among differentially regulated miRNA species, the miR-200 family was downregulated in Akt2-expressing cells. Akt1 knockdown inhibited expression of miR-200 and promoted TGFβ-induced epithelial-mesenchymal-transition (EMT) and a stem cell like phenotype. Carcinomas developing in MMTV-cErb2/Akt1 | 2012-01-26 |
20120021984 | Glycoprotein Hormone Analogs - This invention relates to the field of glycoprotein hormone analogs and their uses as agonists, antagonists, targeting vectors, and immunogens. In particular, this invention describes a method for stabilizing a heterodimer that permits the preparation of functional glycoprotein hormone analogs. The analogs of present invention comprise at least one alpha subunit polypeptide and at least one beta subunit polypeptide, wherein the seatbelt region of the beta subunit is linked to the alpha subunit. The invention also provides for a beta subunit polypeptide wherein the C-terminal amino acid is from residue 10 to residue 20 of the seatbelt region. | 2012-01-26 |
20120021985 | ALBUMIN FUSION PROTEINS - The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention. | 2012-01-26 |
20120021986 | PROTECTING AND REPAIRING CARTILAGE AND MUSCULOSKELETAL SOFT TISSUES - Provided herein are compositions and methods related to promoting protection or repair of articular cartilage and/or musculoskeletal soft tissue by contacting the cartilage, tissues or cellular components thereof with a parathyroid hormone/parathyroid hormone-related protein (PTH/PTHrP) receptor agonist or releasing factor. | 2012-01-26 |
20120021987 | Mucin 3 EGF-Like Domains - The invention provides for a mucin3 polypeptide, a polypeptide including a mucin3 EGFlike domain, and nucleic acids encoding such polypeptides. The invention also provides for methods of treating an individual that has or is at risk of developing a disease or condition of the alimentary canal using such polypeptides or nucleic acids. | 2012-01-26 |
20120021988 | METHODS FOR TREATING IMMUNE THROMBOCYTOPENIA - Polypeptides and other compounds that can bind specifically to the C | 2012-01-26 |
20120021989 | GENETIC MARKERS FOR RISK MANAGEMENT OF ATRIAL FIBRILLATION AND STROKE - The invention relates to procedures and methods of determining a susceptibility to cardiac arrhythmia, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with risk of these conditions. The invention further relates to kits encompassing reagents for assessing such markers, and diagnostic 5 methods, uses and procedures for utilizing such susceptibility markers. | 2012-01-26 |
20120021990 | PEPTIDES USEFUL AS DUAL CASPASE-2/-6 INHIBITORS AND THEIR BIOLOGICAL APPLICATIONS - The present disclosure relates to peptides having a core sequence as described herein as well as application of the disclosed technology as inhibitors of caspase-2 and/or -6 activity. | 2012-01-26 |
20120021991 | USE OF A BOTULINUM NEUROTOXIN TO ALLEVIATE VARIOUS DISORDERS - Methods for treating obsessions and compulsions by local administration of a Clostridial toxin. The obsessions or compulsions can be eye poking, body rocking, finger biting, counting, checking and related disorders treated by low dose, intramuscular administration of a botulinum toxin. | 2012-01-26 |
20120021992 | METHODS FOR IMPROVING NEUROLOGICAL OUTCOME AFTER NEURAL INJURY AND NEURODEGENERATIVE DISEASE - Thymosin β | 2012-01-26 |
20120021993 | PROTEIN SCAFFOLD LIBRARY BASED ON KRINGLE DOMAIN STRUCTURE AND USES THEREOF - There are provided a Kringle domain structure, comprising: inducing artificial mutations at amino acid residues except for conserved amino acid residues that are important to maintain the structural scaffold of a Kringle domain; and protein scaffold variants, based on the Kringle domain structure, which modulate the biological activities of a variety of target molecules derived from the protein scaffold library by specifically binding to the target molecules. Also, there is provided a method for constructing homo-/hetero-oligomers which allow multi-specificity binding to multiple targets by the tandem assembly monomeric Kringle domain variants using a linker. Additionally, there is provided a method for preparing multispecific monomers and multivalent monomers by grafting target-binding loops of a Kringle domain variant into non-binding loops of another Kringle domain variant with the same or different target binding specificity. Furthermore, a protein scaffold variant based on the Kringle domain structure that specifically binds to target molecules, DNA encoding the protein scaffold variant, or a method and composition for prevention, detection, diagnosis, treatment or relieving diseases or disorders, particularly cancers and other immune-related diseases, comprising: administering an effective amount of the related molecule to animals, preferably human. | 2012-01-26 |
20120021994 | NOVEL CANCER ANTIGEN EEF2 - The present invention provides a method for detecting cancer using a protein expressed in various cancers, and a pharmaceutical composition for the treatment or prevention of such cancer using the protein as an indicator. Furthermore, the present invention provides a pharmaceutical composition containing a cancer antigen peptide derived from the protein. More particularly, the method comprises the step of determining the presence or amount of an eEF2 polypeptide or an eEF2 antibody in a sample obtained from a subject. | 2012-01-26 |
20120021995 | Polypeptides that Bind TRAIL-R1 and TRAIL-R2 - Agonists for TRAIL death receptors including polypeptides that bind to TRAIL death receptor TRAIL-R1 (DR4) and/or TRAIL-R2 (DR5) and optionally having a multimerizing, e.g. trimerizing domain. Agonists are described that do not bind to TRAIL decoy receptors. The multimerizing domain may be derived from human tetranectin. The agonists can induce apoptosis in pathogenic cells expressing a TRAIL death receptor. Pharmaceutical compositions are described for treating diseases associated with cells expressing DR4 and DR5, such as tumor cells. Methods for selecting polypeptides and preparing multimeric complexes. | 2012-01-26 |
20120021996 | USING HEAT SHOCK PROTEINS TO IMPROVE THE THERAPEUTIC BENEFIT OF A NON-VACCINE TREATMENT MODALITY - The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an α-2-macroglobulin (α2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an α2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or α2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality. | 2012-01-26 |
20120021997 | USING HEAT SHOCK PROTEINS TO IMPROVE THE THERAPEUTIC BENEFIT OF A NON-VACCINE TREATMENT MODALITY - The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an α-2-macroglobulin (α2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an α2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or α2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality. | 2012-01-26 |
20120021998 | Cancer Diagnosis and Treatment Methods of Use - The present invention relates to a method for treating a subject suffering from growth of AR-containing tumor cells, comprising administrating the subject an effective amount of DDB2. The present invention also relates to a kit for the diagnosis of cancer. | 2012-01-26 |
20120021999 | PRO-APOPTOTIC PEPTIDES - The invention relates to chimeric peptides useful as pro-apoptotic agents, for inhibition of in vitro cell proliferation and for treatment of tumors. | 2012-01-26 |
20120022000 | USE OF A PEPTIDE IN THE TREATMENT OR PREVENTION OF METASTASIS - The present invention relates to a peptide useful for the preparation of a medicament for the treatment or prevention of metastasis. Furthermore, it relates to a method of treatment or prevention of metastasis comprising administering to a subject in need thereof, a therapeutically effective amount of the peptide of the invention. | 2012-01-26 |
20120022001 | METHOD OF MITIGATING ADVERSE DRUG EVENTS USING OMEGA-3 FATTY ACIDS AS A PARENTERAL THERAPEUTIC DRUG VEHICLE - A method of parenterally administering a composition, the method including parenterally administering to a person a composition including at least one omega-3 fatty acid and at least one drug, wherein the at least one omega-3 fatty acid source and the at least one drug are administered simultaneously. | 2012-01-26 |
20120022002 | SUSTAINED RELEASE siRNA FOR OCULAR DRUG DELIVERY - The present invention provides an ocular implant comprising siRNA complexed with a transfection agent selected from the group consisting of cationic lipids and short cell penetration peptides, wherein said complex is associated with a biocompatible polymer. Said biocompatible polymer comprises a polymeric matrix configured to release said complex into the eye of a patient at therapeutic levels for a time sufficient to treat an ocular condition or disease. | 2012-01-26 |
20120022003 | METHOD OF USING DIKETOPIPERAZINES AND COMPOSITION CONTAINING THEM - The invention provides a method of inhibiting the effects of platelet activating factor (PAF). For instance, a disease or condition mediated by PAF (particularly inflammation) can be treated or platelet aggregation can be inhibited. The invention also provides a method of inhibiting the production and/or release of interleukin 8 (IL-8) by cells. The effects of PAF and the production and/or release of IL-8 are inhibited according to the invention by a compound of the formula: | 2012-01-26 |
20120022004 | TREATMENT OF T-CELL MEDIATED DISEASES - The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions. | 2012-01-26 |
20120022005 | Synthetic Dragline Spider Silk-Like Proteins - The present application relates to isolated amino acid sequence comprising multiple repeats of a semi-synthetic spider silk protein domain, or any functional homolog, variant, derivative, fragment or mutant thereof. The amino acid sequence of the invention further comprises an N-terminal region and a C-terminal region. The invention further provides a nucleic acid encoding the amino acid sequence of the invention, an expression vector comprising said nucleic acid, a host cell transformed with said expression vector, a recombinant spider silk protein thus produced and a fiber composed of the recombinant spider silk protein. The invention further encompasses a composition comprising as an active ingredient said amino acid sequence or any said recombinant protein or fiber comprising the same. Lastly, the invention relates to an article comprising at least one fiber composed of said recombinant spider silk protein. | 2012-01-26 |
20120022006 | B-LYMPHOCYTE STIMULATOR BINDING POLYPEPTIDES AND METHODS BASED THEREON - Binding polypeptides that specifically bind B lymphocyte stimulator protein or B lymphocyte stimulator-like polypeptides can be used in methods of the invention for detecting, diagnosing, or prognosing a disease or disorder associated with aberrant B lymphocyte stimulator or B lymphocyte stimulator receptor expression or inappropriate function of B lymphocyte stimulator or B lymphocyte stimulator receptor, comprising B lymphocyte stimulator binding polypeptides or fragments or variants thereof, that specifically bind to B lymphocyte stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B lymphocyte stimulator or B lymphocyte stimulator receptor expression or inappropriate B lymphocyte stimulator function or B lymphocyte stimulator receptor function, comprising administering to an animal, preferably a human, an effective amount of one or more B lymphocyte stimulator binding polypeptides or fragments or variants thereof, that specifically bind to B lymphocyte stimulator. | 2012-01-26 |
20120022007 | METHOD AND COMPOSITION FOR MODULATING CANONICAL WNT PATHWAY USING FOLATE AND INOSITOL - The canonical Wnt signaling pathway is implicated in many disorders including neural tube defects, limb malformations, and heart defects, developmental disorders associated with alcohol exposure (fetal alcohol syndrome) or exposure to bipolar medications (i.e. lithium), wound healing, and Alzheimer's disease. Elevated plasma homocysteine (HCy), which results from folate (folic acid, FA) deficiency, the mood-stabilizing drug lithium (Li), and alcohol (ethanol) are linked to the induction of human congenital heart and neural tube defects. FA supplementation ameliorates the observed developmental errors in the Li-HCy, or alcohol-exposed mouse embryos and normalized heart function. Li, HCy or Wnt3A suppress Wnt-modulated Hex and Islet-1 expression. FA protects from the gene misexpression that is induced by all three factors. Administration of myo-inositol with FA synergistically enhances the protective effect. | 2012-01-26 |
20120022008 | Compounds and Method for Inhibiting the Activity of Gelatinase and Collagenase - Compounds extracted from | 2012-01-26 |
20120022009 | TANNATE DRY POWDER FORMULATIONS - Dry powder tannate compositions containing bioactive agents, tannic acid, dispersants, and viscosity modifying agents are disclosed. Specifically, the bioactive agents are antihistamines, decongestants, antitussives, and anticholinergics. The dry powder formulations can further include pharmaceutically acceptable excipients. The dry powder formulations exhibit increased stability for extended shelf life. Bioactive agent tannate salts remain suspended for at least two weeks following formation of the suspension in a pharmaceutically acceptable aqueous liquid. | 2012-01-26 |
20120022010 | USE OF FLAVONOIDS TO INCREASE THE BIOAVAILABILITY OF HESPERETIN - The present invention relates generally to the field of hesperetin bioavailability. One embodiment of the present invention is directed at a composition that allows to increase the bioavailability of hesperetin and consequently to maximize the beneficial health effects of hesperetin. | 2012-01-26 |
20120022011 | HSP90 INHIBITORS WITH MODIFIED TOXICITY - The invention provides purified 19-substituted geldanamycin derivatives, pharmaceutically acceptable salts thereof and prodrugs thereof that are potent Hsp90 binding agents that are useful for the treatment and/or the amelioration of symptoms of cancer and other proliferative tissue disorders. | 2012-01-26 |
20120022012 | Glycosylated Acetaminophen Pro-Drug Analogs - The present invention relates to methods and compositions for the synthesis, production, and use of pro-drug analogs of the analgesic acetaminophen. This invention relates to a method for the production of a broad group of glycosides of acetaminophen derivatives. | 2012-01-26 |
20120022013 | METHODS AND COMPOSITIONS FOR EXTENDING THE LIFE SPAN AND INCREASING THE STRESS RESISTANCE OF CELLS AND ORGANISMS - The invention provides methods and compositions for modulating the life span of eukaryotic and prokaryotic cells and for protecting cells against certain stresses, e.g., heatshock. One method comprises modulating the flux of the NAD+ salvage pathway in the cell, e.g., by modulating the level or activity of one or more proteins selected from the group consisting of NPT1, PNC1, NMA1 and NMA2. Another method comprises modulating the level of nicotinamide in the cell. | 2012-01-26 |
20120022014 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS - The present disclosure describes tetrahydropyran nucleoside analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, novel tetrahydropyran nucleoside analogs are provided having at least one chiral substituent that are expected to be useful for enhancing one or more properties of oligomeric compounds such as nuclease resistance and/or binding affinity. In certain embodiments, the oligomeric compounds are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. | 2012-01-26 |
20120022015 | METHOD OF TREATMENT AND SUPPLEMENT - A method of treatment and associated nutritional combination is disclosed. The method of treatment includes providing a patient with a nutritional combination including appropriate amounts of riboflavin, pyridoxine hydrochloride, and cyanocobalamin. The combination may further include thiamine mononitrate and calcium pantothenate, and may be in the form of an oral supplement such as a capsule or tablet. Alternatively, the combination may be a fluid for intravenous intake, and may further include thiamine hydrochloride, D-panthenol, water, benzyl alcohol, and sodium chloride. The treatement and combination of ingredients works synergistically together and is particularly effective in enhancing nerve regeneration in a variety of patients. | 2012-01-26 |
20120022016 | Compounds and methods for selectively targeting tumor-associated mucins - The present invention relates to pharmaceutical compositions containing tumor-selective targeted inhibitor glycoconjugates. These bioconjugates are ALK5 inhibitors covalently bound to biocompatible carrier molecules which selectively target and specifically bind to Muc4 that is overexpressed on a variety of tumor cell types. The ALK5 inhibitors are conjugated to tumor targetable glycans through a covalent linker. Preferably the acid-labile linker is designed to be stable in plasma and releases pharmacologically active inhibitors through acid-catalyzed hydrolysis in the acidic environment of the target tumor where the inhibitor activity is restored. Because the glycoconjugates are stable at physiological pH and in plasma, they advantageously reduce undesirable systemic ALK5 inhibitor activity; however, the preferable glycoconjugates are acid-labile conjugates that can be hydrolyzed upon reaching the more acid environment of the tumor. | 2012-01-26 |
20120022017 | COMPOSITION AND A METHOD THEREOF - The present invention describes a palatable and orally administrable form of composition comprising proteins, galactomannans and base matrix optionally along with acceptable additives. | 2012-01-26 |
20120022018 | ANTI-VIRAL PROPERTIES OF ALOE VERA AND ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) TREATMENT - A pharmaceutical composition comprising a combination of formulations derived from Aloe vera for the treatment of Acquired Immune Deficiency Syndrome (AIDS) or HIV infection is described herein. The composition comprises: (i) an injectable sterile polymannan extract, (ii) Raidox (aloe anthraquinones and their diacetyl derivatives), and (iii) a freeze dried aloe vera powder, aloe vera juice, aloe gel or a combination. In addition one or more nutritional supplements comprising fatty acids, proteins, minerals and metals, vitamins, salts, amino acids, and other pharmaceutically acceptable excipients may also be include to counteract the chronic diarrhea, digestive upsets, and weight loss seen in some patients before and during the treatment course. A method for treating the AIDS or HIV infection using the composition of the present invention is also disclosed. | 2012-01-26 |
20120022019 | Medicinal Steroids Cream And A Process To Make It - The present invention relates to a composition for treating skin inflammation, along with skin rejuvenation. More particularly, the present invention relates to a pharmaceutical cream comprising a biopolymer, and a corticosteroid. It discloses a composition for treating skin inflammation, along with skin rejuvenation containing a) a biopolymer in the form of chitosan, b) an active ingredient such as a corticosteroid used in treating skin inflammations, c) a cream base containing primary and secondary emulsifiers, waxy materials, co-solvents, acids, preservatives, buffering agents, anti oxidants, chelating agents, and humectants, and d) water. The active ingredients, namely chitosan, and a corticosteroid, are incorporated in cream base for use in treating skin inflammation. | 2012-01-26 |
20120022020 | PHARMACEUTICAL FORMS FOR THE RELEASE OF ACTIVE COMPOUNDS - A pharmaceutical composition containing a sulfated glycosaminoglycan drug and a polycationic polymer or copolymer wherein the proportion of ammonium groups in the pharmaceutical composition is between 0.01-2.0 μmol ammonium groups/mg pharmaceutical composition, the proportion of glycosaminoglycan in the pharmaceutical form is between 15% to 50% w/w, and the pharmaceutical composition possesses a moisture content of 10% wt or less. A pharmaceutical dosage form containing the pharmaceutical composition, and their use for the treatment of diseases or disorders therapeutically responsive to the glycosaminoglycan. | 2012-01-26 |
20120022021 | Mixtures of strobilurins with 1-methylcyclopropene - The present invention relates to mixtures comprising
| 2012-01-26 |
20120022022 | NOVEL INHIBITORS OF CHYMASE - The present invention is directed to a compound of formula (I), | 2012-01-26 |
20120022023 | Hydraulic Cements, Methods and Products - Non-aqueous hydraulic cement compositions comprise a non-aqueous mixture of a powder composition and a non-aqueous water-miscible liquid. In one embodiment, powder composition is a Brushite or Monetite-forming calcium phosphate powder composition. In another embodiment, the powder composition comprises porous β-tricalcium phosphate (β-TCP) granules and at least one additional calcium phosphate powder. In another embodiment, the powder composition comprises calcium silicate powder. In a further embodiment, the powder composition comprises calcium aluminate powder. In another embodiment, the powder composition is a cement composition and comprises nanopowders having a grain size of less than | 2012-01-26 |
20120022024 | ANTI-BACTERIAL COMPOSITIONS AND METHODS INCLUDING TARGETING VIRULENCE FACTORS OF STAPHYLOCOCCUS AUREUS - This disclosure relates to compositions and methods including for the inhibition, prevention, and/or treatment of microbial infections, including infections from such pathogens as | 2012-01-26 |
20120022025 | CRYSTALLINE FORM C OF TIGECYCLINE DIHYDROCHLORIDE AND METHODS FOR ITS PREPARATION - The present invention relates to crystalline form C of Tigecycline dihydrochloride and to methods for the preparation of the same. Furthermore the present invention relates to the use of crystalline form C of Tigecycline dihydrochloride as an intermediate for the preparation of an anti-infective medicament. Moreover the present invention relates to pharmaceutical compositions comprising crystalline form C of Tigecycline dihydrochloride in an effective amount and to the use of crystalline form C of Tigecycline dihydrochloride as an anti-infective medicament. | 2012-01-26 |
20120022026 | METHOD OF TREATING CANCER - The present invention relates to a method of treating or preventing hyperproliferative disease in a body tissue of a subject, comprising the steps of administering to a subject in need thereof a therapeutically effective amount of an agent that induces double strand breaks in the DNA of the hyperproliferative cells of said body tissue; and subjecting the hyperproliferative cells of said body tissue prior to, simultaneously with or subsequent to step a) to hyperthermia to thereby induce in said cells the degradation, inhibition and/or inactivation of BRCA2. | 2012-01-26 |
20120022027 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES - Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel semicarbazides, sulfonyl carbazides, ureas and related compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to Arenaviridae (Junin, Machupo, Guanavito, Sabia and Lassa), Filoviridae (ebola and Marburg viruses), Flaviviridae (yellow fever, omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever). | 2012-01-26 |
20120022029 | TOPICAL PAIN RELIEVER AND METHOD OF MAKING THE SAME - A topical pain reliever and method of making the same is disclosed. The topical pain reliever may comprise effective amounts of water, glycerine, analgesic agent such as salicylic acid or a derivative thereof, and alcohol. The method of making the topical pain reliever may maintain the analgesic agent in suspension within a solution. The topical pain reliever may be applied to the skin of a user to provide pain relief without ingestion of the composition, thereby potentially avoiding adverse side effects. | 2012-01-26 |
20120022030 | Tetracyclic Lactame Derivatives - The present invention describes tetracyclic compounds of formula (IA) or (IB), | 2012-01-26 |
20120022031 | COMPOSITION AND METHODS OF TREATMENT OF BACTERIAL MENINGITIS - A diluted solution of ceftiofur sodium is intrathecally or ventricularly delivered to effectively treat bacterial meningitis while maintaining the patient's threshold and reducing the likelihood of seizure. | 2012-01-26 |
20120022032 | CORTICOSTEROID COMPOSITIONS AND METHODS OF TREATMENTS THEREOF - This invention relates to steroidal solutions for the preparation of medicaments and drug products useful for treating diseases of the upper and lower airway passages. Various embodiments of the present invention provide compositions, compositions and dosage forms with mometasone furoate in a dissolved state that are suitable for inhalation and can be used for the treatment of diseases of the upper and/or lower airway passages. | 2012-01-26 |
20120022033 | Methods for decreasing cardiovascular risk in postmenopausal women - Methods for decreasing the risk of cardiovascular events in postmenopausal women having a high risk for a cardiovascular event are provided. In particular, methods for decreasing the risk of cardiovascular events in postmenopausal woman at high risk for cardiovascular events by administering to the woman a therapeutically effective amount of an androgen, whereby administering the androgen decreases the risk of cardiovascular events in the woman compared to untreated postmenopausal woman at high risk for cardiovascular events are provided. | 2012-01-26 |
20120022034 | METHODS FOR REDUCING OR NEOVASCULARIZATION OR EDEMA - Methods for reducing or preventing neovascularization or edema in the eye by implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer. | 2012-01-26 |
20120022035 | Polymorphic and Amorphous Salt Forms of Squalamine Dilactate - The invention relates to select squalamine salts, methods of their synthesis, their therapeutic use and their advantages relating to manufacturing, product stability and toxicity. More specifically, this application is directed to various forms of the dilactate salt of squalamine and their utility in inhibiting neovascularization and endothelial cell proliferation. | 2012-01-26 |
20120022036 | Method of treating osteoporosis - A method for treating osteoporosis and related methods are disclosed. The methods generally comprise administering to a patient in need of treatment an effective amount of tris(8-quinolinolato)gallium(III) or an analog thereof. | 2012-01-26 |
20120022037 | AQUEOUS HAIR CLEANSING AGENT - The present invention relates to an aqueous hair cleansing agent which includes the following components (A), (B): (A) sulfate-type anionic surfactant having a specific structure, (B) polyoxyethylene alkyl ether-type nonionic surfactant having a specific structure, and water, wherein ratio of weight represented by (B)/((A)+(B)) is 1% to 25%. | 2012-01-26 |
20120022038 | ANIMAL TREATMENT FORMULATION AND METHODS OF USE - The present invention relates to a formulation for administration to the teat canal of the mammary gland of an animal, the formulation including: a physical barrier material, characterised in that the formulation includes sufficient antibiotic in relation to physical barrier material such that the formulation is configured to disintegrate over a period of time after administration to the teat canal. | 2012-01-26 |
20120022039 | NOVEL SUBSTITUTED INDANES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS - The invention relates to substituted indanes and derivatives thereof, to physiologically acceptable salts and physiologically functional derivatives thereof, to the production thereof, to drugs containing at least one substituted indane according to the invention or derivative thereof, and to the use of the substituted indanes according to the invention and to derivatives thereof as MCH antagonists. | 2012-01-26 |
20120022040 | ANTIMICROBIALS - Compounds useful as antimicrobials are provided, as are methods of use and preparation of such compounds and compositions containing such compounds. In one embodiment, the compounds are derivatives having a carbapenem core, and are useful for treating a microorganism infection. | 2012-01-26 |
20120022041 | SUBSTITUTED HETEROCYCLIC COMPOUNDS - Disclosed are compounds of Formula (I) | 2012-01-26 |
20120022042 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS - The present invention relates to the use of a compound of formula I | 2012-01-26 |
20120022043 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS - The invention provides JAK kinase inhibitors of Formula Ia, enantiomers, diasteriomers or pharmaceutically acceptable salts thereof, wherein R | 2012-01-26 |
20120022044 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE - According to the invention there is provided a compound of formula I or a pharmaceutically acceptable salt or hydrate thereof; wherein the variables are as defined herein. The compounds selectively attenuate the production of Aβ42 and hence are useful in treatment of Alzheimer's disease and related conditions. | 2012-01-26 |
20120022045 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS - Compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: the asterisk * in Q denotes the point of attachment to the rest of the compound; and n, L1, L2, X | 2012-01-26 |
20120022046 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections - Methods and pharmaceutical compositions for treating viral infections, by administering certain thienopyridine derivative compounds in therapeutically effective amounts are disclosed. Methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by flavivirus is disclosed, i.e., including but not limited to, Dengue virus, West Nile virus, yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus. | 2012-01-26 |
20120022047 | PROCESS FOR THE PURIFICATION OF ESLICARBAZEPINE ACETATE - The present invention relates to the purification and particle size of eslicarbazepine acetate. The present invention also relates to the physical characteristics of solid state eslicarbazepine acetate, and pharmaceutical compositions containing the same. | 2012-01-26 |
20120022048 | Anti-proliferative substituted pyrazolo[3,4-d]pyrimidines derivatives (SPP) to inhibit immune activation, virus replication and tumor growth - A family of pyrazolo[3,4-d]pyrimidine derivatives (SPPs) with different substituents on the pyrimidine and pyrazolo rings have been characterized with a panel of tests demonstrating their effects in cell proliferation, toxicity, apoptosis and inhibition of virus replication. We have identified compounds and molecular structures suitable for the treatment of viral infection because they have antiviral activity, anti-proliferative activity or, preferably, both so that, as a single molecule, they both limit T cell hyperactivation and inhibit virus replication. These compounds are not toxic at effective concentrations and are poorly apoptotic. Other nontoxic compounds within this family with excellent anti-proliferative and apoptotic features are potentially effective as anti-cancer drugs. | 2012-01-26 |